New anticoagulation strategy tested for dialysis circuits in ECMO patients

NCT ID NCT05148026

Completed Disease control Sponsor: University of Milano Bicocca Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether adding regional citrate anticoagulation (RCA) to standard heparin can reduce clotting in continuous kidney dialysis circuits for patients on ECMO. Eighteen ICU adults with ARDS and acute kidney injury were enrolled. Each patient received alternating periods with and without citrate to compare circuit clotting rates.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Regional citrate anticoagulation (RCA) plus unfractionated heparin
What this could lead to: If adding citrate works, it could reduce clotting in dialysis circuits during ECMO, making treatment safer and more efficient for critically ill patients.
What could go wrong: This is a very small, early-stage study (18 patients) testing a technique already used in other settings. Results may not apply broadly, and adding citrate could increase bleeding or metabolic risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute kidney injury acute respiratory distress syndrome adult acute respiratory distress syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE KIDNEY INJURY ARDS, HUMAN

Contacts and locations

Locations

ASST MONZA-Rianimazione Generale

Monza, Italy, 20900, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.